2018 Q1 Form 10-Q Financial Statement

#000143774918009748 Filed on May 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $210.0K -$10.00K
YoY Change -2200.0% -105.88%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $808.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $210.0K -$10.00K
YoY Change -2200.0% -105.88%
Operating Profit -$208.8K $7.270K
YoY Change -2972.09% -104.3%
Interest Expense $384.00 $12.28K
YoY Change -96.87%
% of Operating Profit 168.89%
Other Income/Expense, Net
YoY Change
Pretax Income -$210.0K -$10.00K
YoY Change 2000.0% -94.12%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$209.2K -$5.008K
YoY Change 4077.02% -97.04%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$80.46K -$9.434K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $480.0K $670.0K
YoY Change -28.36% 272.22%
Cash & Equivalents $479.3K $673.0K
Short-Term Investments
Other Short-Term Assets $30.00K $20.00K
YoY Change 50.0% 100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $509.9K $690.0K
YoY Change -26.1% 261.9%
LONG-TERM ASSETS
Property, Plant & Equipment $21.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $21.00K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $509.9K $690.0K
Total Long-Term Assets $21.00K $0.00
Total Assets $530.9K $690.0K
YoY Change -23.05% 261.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $50.00K $70.00K
YoY Change -28.57% 0.0%
Accrued Expenses $30.70K
YoY Change 2616.55%
Deferred Revenue
YoY Change
Short-Term Debt $20.00K $340.0K
YoY Change -94.12%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $98.62K $780.0K
YoY Change -87.36% 136.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $98.62K $780.0K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $98.62K $780.0K
YoY Change -87.36% 136.99%
SHAREHOLDERS EQUITY
Retained Earnings -$111.5M
YoY Change
Common Stock $26.11K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 5.655K shares
Shareholders Equity $432.3K -$80.00K
YoY Change
Total Liabilities & Shareholders Equity $530.9K $690.0K
YoY Change -23.05% 261.9%

Cashflow Statement

Concept 2018 Q1 2017 Q1
OPERATING ACTIVITIES
Net Income -$209.2K -$5.008K
YoY Change 4077.02% -97.04%
Depreciation, Depletion And Amortization $808.00 $0.00
YoY Change
Cash From Operating Activities -$216.6K $29.16K
YoY Change -842.88% -119.94%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $110.0K
YoY Change -100.0%
Cash From Investing Activities $110.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $675.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -12.50K 533.4K
YoY Change -102.34%
NET CHANGE
Cash From Operating Activities -216.6K 29.16K
Cash From Investing Activities 110.0K
Cash From Financing Activities -12.50K 533.4K
Net Change In Cash -229.1K 672.6K
YoY Change -134.07% -560.0%
FREE CASH FLOW
Cash From Operating Activities -$216.6K $29.16K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 mamp Decrease In Accrued Interest Related Party
DecreaseInAccruedInterestRelatedParty
CY2017Q1 mamp Decrease In Accrued Interest Related Party
DecreaseInAccruedInterestRelatedParty
-12278
CY2018Q1 mamp General And Administrative Expense Reversal
GeneralAndAdministrativeExpenseReversal
208801
CY2017Q1 mamp General And Administrative Expense Reversal
GeneralAndAdministrativeExpenseReversal
-7270
CY2018Q1 mamp Net Working Capital
NetWorkingCapital
411000
CY2018Q1 mamp Percentage Of Income Tax Examination Likelihood Of Tax Benefits Being Realized Upon Settlement
PercentageOfIncomeTaxExaminationLikelihoodOfTaxBenefitsBeingRealizedUponSettlement
0.5
CY2018Q1 mamp Preferred Stock Amount Of Preferred Dividends Undeclared And Unaccrued
PreferredStockAmountOfPreferredDividendsUndeclaredAndUnaccrued
6250
CY2018Q1 mamp Preferred Stock Dividend In Excess Of Payments
PreferredStockDividendInExcessOfPayments
CY2017Q1 mamp Preferred Stock Dividend In Excess Of Payments
PreferredStockDividendInExcessOfPayments
25945
CY2018Q1 mamp Proceeds From Common Stock Subscribed Net Of Expenses
ProceedsFromCommonStockSubscribedNetOfExpenses
CY2017Q1 mamp Proceeds From Common Stock Subscribed Net Of Expenses
ProceedsFromCommonStockSubscribedNetOfExpenses
675000
CY2018Q1 mamp Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
CY2017 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue
0
CY2018Q1 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Expired In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue
0
CY2017 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
0
CY2018Q1 mamp Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
CY2018Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
50565
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
66319
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1616
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
111861799
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
111861799
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10375
CY2018Q1 us-gaap Assets
Assets
530942
CY2017Q4 us-gaap Assets
Assets
768381
CY2018Q1 us-gaap Assets Current
AssetsCurrent
509942
CY2017Q4 us-gaap Assets Current
AssetsCurrent
746573
CY2018Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
21000
CY2017Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
21808
CY2018Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> Principles of Consolidation and Basis of Presentation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany account balances have been eliminated in consolidation. The accompanying Financial Statements give effect to all adjustments necessary to present fairly the financial position and results of operations and cash flows of the Company and its subsidiaries.</div></div>
CY2018Q1 us-gaap Cash
Cash
479000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
708382
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
450
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
479252
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
673043
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-229130
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
672593
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2610568
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2610568
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
26105
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
26105
CY2017Q3 us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
148125
CY2016Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
110000
CY2018Q1 us-gaap Depreciation
Depreciation
808
CY2017Q1 us-gaap Depreciation
Depreciation
CY2018Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
27361
CY2017Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
27361
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0
CY2018Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5650
CY2017Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-15753
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11969
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6258
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7500
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-9922
CY2018Q1 us-gaap Interest Expense
InterestExpense
384
CY2017Q1 us-gaap Interest Expense
InterestExpense
12278
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2017Q1 us-gaap Interest Paid Net
InterestPaidNet
CY2018Q1 us-gaap Liabilities
Liabilities
98617
CY2017Q4 us-gaap Liabilities
Liabilities
126871
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
530942
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
768381
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
98617
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
126871
CY2018Q1 us-gaap Loans Payable Current
LoansPayableCurrent
20691
CY2017Q4 us-gaap Loans Payable Current
LoansPayableCurrent
33191
CY2018Q1 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Nature of Operations</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:39.6pt;">MedAmerica Properties Inc. (the &#x201c;Company&#x201d; or &#x201c;MedAmerica&#x201d;), was originally organized under the laws of the Commonwealth of Massachusetts in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1985,</div> under the name VMS Hotel Investment Trust, for the purpose of investing in mortgage loans. The Company was subsequently reorganized as a Delaware corporation in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1987</div> and changed its name to B.H.I.T. Inc. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010,</div> the Company changed its name from B.H.I.T. Inc. to Banyan Rail Services Inc. From <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2012,</div> the Company experienced severe losses from an operating subsidiary in the rail services sector. In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> after exploring various industries and researching numerous companies, the board of directors elected to pursue investing in commercial real estate. The Company is pursuing the acquisition and management of strategically located medical office buildings.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:3.3pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:35.2pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2017, </div>our board of directors and the holders of a majority of our outstanding shares of common stock approved by written consent amendments to the Company&#x2019;s certificate of incorporation to (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) change the name of the Company from &#x201c;Banyan Rail Services Inc.&#x201d; to &#x201c;MedAmerica Properties Inc.,&#x201d; and (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) effect a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> reverse stock split of the issued and outstanding shares of common stock of the Company. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 15, 2017, </div>the Company filed these amendments with the Secretary of State of the State of Delaware and the name change and reverse stock split became effective with the Financial Industry Regulatory Authority, Inc. (&#x201c;FINRA&#x201d;) on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 20, 2017. </div>As appropriate, all common stock share quantities have been updated to reflect the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> reverse stock split.</div></div>
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-12500
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
533432
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
110000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-216630
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
29161
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-209185
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5008
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-210435
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-208801
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
7270
CY2017 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
27361
CY2018Q1 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
27361
CY2018Q1 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.1
CY2018Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1250
CY2017Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1250
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000
CY2018Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2018Q1 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
30690
CY2017Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
38191
CY2017 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1940005
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1940005
CY2018Q1 us-gaap Proceeds From Mortgage Deposits
ProceedsFromMortgageDeposits
CY2017Q1 us-gaap Proceeds From Mortgage Deposits
ProceedsFromMortgageDeposits
110000
CY2018Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
CY2017Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
126533
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22616
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2018Q1 us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;">Equipment and Furnishings</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Equipment and furnishings are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div> years. Expenditures for repairs and maintenance are charged to expense as incurred. For assets sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any related gain or loss is reflected in income for the period statement of operations.</div></div></div></div></div>
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21808
CY2018Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
12500
CY2017Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
CY2018Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
CY2017Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
268101
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111455584
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111246399
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
60000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
60000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
60000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
60000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y182D
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
60000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
432325
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
641510
CY2018Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">The preparation of financial statements, in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"), requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses and disclosures of contingent assets and liabilities at the date and period ending of the financial statements. Actual results could differ from those estimates.</div></div></div></div></div>
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2610568
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1056723

Files In Submission

Name View Source Status
0001437749-18-009748-index-headers.html Edgar Link pending
0001437749-18-009748-index.html Edgar Link pending
0001437749-18-009748.txt Edgar Link pending
0001437749-18-009748-xbrl.zip Edgar Link pending
ex_113372.htm Edgar Link pending
ex_113373.htm Edgar Link pending
ex_113374.htm Edgar Link pending
ex_113375.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mamp-20180331.xml Edgar Link completed
mamp-20180331.xsd Edgar Link pending
mamp-20180331_cal.xml Edgar Link unprocessable
mamp-20180331_def.xml Edgar Link unprocessable
mamp-20180331_lab.xml Edgar Link unprocessable
mamp-20180331_pre.xml Edgar Link unprocessable
mamp20180331_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending